Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 1
1975 6
1976 4
1977 8
1978 1
1979 15
1980 17
1981 21
1982 17
1983 23
1984 40
1985 29
1986 40
1987 43
1988 31
1989 39
1990 44
1991 33
1992 54
1993 47
1994 37
1995 39
1996 37
1997 52
1998 53
1999 52
2000 56
2001 82
2002 68
2003 62
2004 69
2005 54
2006 67
2007 72
2008 81
2009 69
2010 88
2011 102
2012 88
2013 112
2014 119
2015 101
2016 69
2017 65
2018 81
2019 88
2020 107
2021 100
2022 72
2023 62
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

2,481 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean t killer[Author] (115 results)?
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ. Kantarjian HM, et al. Among authors: koller c. J Clin Oncol. 2000 Feb;18(3):547-61. doi: 10.1200/JCO.2000.18.3.547. J Clin Oncol. 2000. PMID: 10653870 Clinical Trial.
Median age was 39.5 years; 37% were at least 50 years old. Mature B-cell disease (Burkitt type) was present in 9%, T-cell disease in 17%. Leukocytosis of more than 30 x 10(9)/L was found in 26%, Philadelphia chromosome-positive disease in 16% (20% of patients with assessab …
Median age was 39.5 years; 37% were at least 50 years old. Mature B-cell disease (Burkitt type) was present in 9%, T-cell disease in …
Sjögren's syndrome.
Delaleu N, Jonsson R, Koller MM. Delaleu N, et al. Among authors: koller mm. Eur J Oral Sci. 2005 Apr;113(2):101-13. doi: 10.1111/j.1600-0722.2004.00183.x. Eur J Oral Sci. 2005. PMID: 15819815 Review.
The salivary and lacrimal glands from patients with SS harbor unique and highly selected T- and B-cell populations. Disturbance in glandular cell apoptosis may be one possible explanation for the sicca symptoms in SS. ...
The salivary and lacrimal glands from patients with SS harbor unique and highly selected T- and B-cell populations. Disturbance in gl …
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
Aldoss I, Afkhami M, Yang D, Gu Z, Mokhtari S, Shahani S, Pourhassan H, Agrawal V, Koller P, Arslan S, Tomasian V, Al Malki MM, Artz A, Salhotra A, Ali H, Aribi A, Sandhu KS, Ball B, Otoukesh S, Amanam I, Becker PS, Stewart FM, Curtin P, Smith E, Telatar M, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. Aldoss I, et al. Among authors: koller p. Am J Hematol. 2023 Jun;98(6):848-856. doi: 10.1002/ajh.26908. Epub 2023 Mar 16. Am J Hematol. 2023. PMID: 36880203
Patients were treated with 149 individual novel regimens (blinatumomab = 83, inotuzumab ozogamicin [InO] = 36, and CD19CAR T cells = 30). The median age at first novel salvage therapy was 36 years (range; 18-71). ...Blinatumomab was administered at an older age compared to …
Patients were treated with 149 individual novel regimens (blinatumomab = 83, inotuzumab ozogamicin [InO] = 36, and CD19CAR T cells = …
The interplay between the gut microbiota and the immune system.
Geuking MB, Köller Y, Rupp S, McCoy KD. Geuking MB, et al. Among authors: koller y. Gut Microbes. 2014 May-Jun;5(3):411-8. doi: 10.4161/gmic.29330. Epub 2014 Jun 12. Gut Microbes. 2014. PMID: 24922519 Free PMC article. Review.
Caffeine and tremor.
Koller W, Cone S, Herbster G. Koller W, et al. Neurology. 1987 Jan;37(1):169-72. doi: 10.1212/wnl.37.1.169. Neurology. 1987. PMID: 3796831
Chemical-induced immunomodulation.
Koller LD. Koller LD. J Am Vet Med Assoc. 1982 Nov 15;181(10):1102-6. J Am Vet Med Assoc. 1982. PMID: 6816774 Review. No abstract available.
Epidemiology and genetics of essential tremor.
Brin MF, Koller W. Brin MF, et al. Among authors: koller w. Mov Disord. 1998;13 Suppl 3:55-63. doi: 10.1002/mds.870131310. Mov Disord. 1998. PMID: 9827596 Review.
[Chronic inflammatory demyelinating polyneuropathy].
Köller H, Kieseier BC, Jander S, Hartung HP. Köller H, et al. Nervenarzt. 2003 Apr;74(4):320-33. doi: 10.1007/s00115-003-1486-5. Nervenarzt. 2003. PMID: 12707701 Review. German.
2,481 results